Products for Research Use Only

Mozavaptan-d6

CAT: 0804-HY-18346S-01Size: 500 µgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18346S-01Size:500 µg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment[1][2].
CAS Number
2750534-83-7
Product Name Alternative
OPC-31260-d6
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Vasopressin Receptor
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Others
Field of Research
Cancer; Endocrinology; Metabolic Disease
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(C=C1)NC(C2=C(C=CC=C2)C)=O)N3C4=CC=CC=C4C(CCC3)N(C([2H])([2H])[2H])C([2H])([2H])[2H]
Molecular Formula
C27H23D6N3O2
Molecular Weight
433.58
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Yamamura Y, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol. 1992 Apr;105 (4) :787-91.|[3]Yamaguchi K, et al. Clinical implication of the antidiuretic hormone (ADH) receptor antagonist mozavaptan hydrochloride in patients with ectopic ADH syndrome. Jpn J Clin Oncol. 2011 Jan;41 (1) :148-52.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Isoform
V2 Receptor